Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29828627 | 1.00 | WEE1 (0.33) | WEE1APPBACE1MAP3K14 | |
| SCHEMBL30594670 | 1.00 | WEE1 (0.33) | WEE1APPBACE1MAP3K14 | |
| SCHEMBL23364855 | 1.00 | WEE1 (0.33) | WEE1APPBACE1MAP3K14 | |
| SCHEMBL24881036 | 0.95 | GRIN2D (0.33) | WEE1MAP3K14 | |
| SCHEMBL21334000 | 0.90 | MAP3K14 (0.32) | WEE1MAP3K14 | |
| SCHEMBL21332753 | 0.90 | MAP3K14 (0.32) | WEE1MAP3K14 | |
| SCHEMBL21349674 | 0.90 | MAP3K14 (0.32) | WEE1MAP3K14 | |
| SCHEMBL25100755 | 0.84 | NR3C1 (0.34) | WEE1MAP3K14 | |
| SCHEMBL23364936 | 0.84 | NR3C1 (0.34) | WEE1MAP3K14 | |
| SCHEMBL23364932 | 0.84 | NR3C1 (0.34) | WEE1MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028363-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | RECURIUM IP HOLDINGS LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12410204-B2 | Chiral synthesis of a tertiary alcohol | RECURIUM IP HOLDINGS, LLC (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4566612-A2 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | Recurium IP Holdings, LLC (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-3762385-B1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS LLC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240391924-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2024-11-28 | — | — | US | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-117720541-A | Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones | 里科瑞尔姆IP控股有限责任公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117285532-A | Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones | 里科瑞尔姆IP控股有限责任公司 | 2023-12-26 | — | — | CN | disclosed |
| US-11261192-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones | RECURIUM IP HOLDINGS, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2022-01-27 | — | — | US | disclosed |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2022-01-27 | — | — | US | disclosed |
| WO-2021097139-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | RECURIUM IP HOLDINGS, LLC (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2021-05-13 | — | — | US | disclosed |
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2021-05-13 | — | — | US | disclosed |
| EP-3762385-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | Recurium IP Holdings, LLC (US) | 2021-01-13 | — | — | EP | disclosed |
| CN-111902413-A | Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones | 里科瑞尔姆IP控股有限责任公司 | 2020-11-06 | — | — | CN | disclosed |
| WO-2019173082-A1 | SUBSTITUTED L,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | Zeno Royalties & Milestones, LLC (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019173082-A1 | SUBSTITUTED L,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | Zeno Royalties & Milestones, LLC (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261192-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones | MKI67, BRCA1, CCNI | WEE1 2009/4885APP 3399/4885BACE1 3046/4885 |
| US-12410204-B2 | Chiral synthesis of a tertiary alcohol | ADH1A, ADH1C, ADH5 | WEE1 640/4885APP 4740/4885BACE1 4599/4885 |
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | WEE1 2009/4885APP 3399/4885BACE1 3046/4885 |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | WEE1 2009/4885APP 3399/4885BACE1 3046/4885 |
| US-20240391924-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | WEE1 2009/4885APP 3399/4885BACE1 3046/4885 |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | WEE1 1/4885APP 4769/4885BACE1 3467/4885 |
| US-20260028363-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | ADH1A, ADH1C, ADH5 | WEE1 92/4885APP 3942/4885BACE1 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.